论文部分内容阅读
2008年开始,烟酰胺市场便在酝酿一场变革。2010年,当全球金融危机的影响不断深层次发酵,国内外市场对烟酰胺的热衷非但没有减退,而且愈演愈烈:龙沙通过扩产来巩固其市场地位;凡特鲁斯也对上游中间体3-甲基吡啶进行积极扩产,同时对外宣告将投产烟酰胺;许多国内企业新产品投放市场,新上马的烟酰胺项目均声称已经突破了烟酰胺生产面临的原料来源和关键技术问题。供应商的增多将使原有的市场格局被打破,作为全球吡啶生产领先企业,吉友联化学有限公司(本文简称“吉友联”)又将如何设计自己的市场策略?本期,由吉友联化学维生素事业部总经理Manoj Khullar先生为您解读。
Since 2008, nicotinamide market is brewing a revolution. In 2010, when the impact of the global financial crisis was constantly deepened and fermented, the enthusiasm for nicotinamide in domestic and foreign markets not only did not diminish but intensified: Lonza strengthened its market position through expansion of production; - picoline to actively expand production, at the same time announced that it will put into operation nicotinamide; many domestic enterprises to launch new products on the market, the newly launched niacinamide project claimed to have exceeded the nicotinamide production is facing the sources of raw materials and key technical issues. The increase of suppliers will make the original market structure be broken. As a leading global producer of pyridine, Kyrgyzstan Union Chemical Co., Ltd. (hereinafter referred to as “Kyrgyzstan Union”) and how to design their own marketing strategy? In this issue, Manoj Khullar, General Manager, Kyrgyzstan’s Department of Chemical Vitamins explains it for you.